Literature DB >> 12773544

Production, characterization, and immunogenicity of a soluble rat single chain T cell receptor specific for an encephalitogenic peptide.

Rachel H McMahan1, Lisa Watson, Roberto Meza-Romero, Gregory G Burrows, Dennis N Bourdette, Abigail C Buenafe.   

Abstract

The encephalitogenic rat T cell clone C14 recognizes the myelin basic protein 69-89 peptide in the context of the RT1B major histocompatibility complex (MHC) class II molecule. Modeling of the C14 TCR molecule indicated that previously identified CDR3 motifs are likely to be central to interaction with MHC class II-presented peptide. Here we report the cloning and expression of C14-derived single chain TCR (scTCR) molecules in an Escherichia coli expression system. The recombinant molecule consists of the Valpha2 domain connected to the Vbeta8.2 domain via a 15-residue linker. Soluble C14 scTCR was purified using conventional chromatography techniques and refolded by a rapid dilution procedure. C14 scTCR was able to bind soluble rat MHC class II molecules bearing covalently coupled Gp-BP-(69-89) peptide, as analyzed using surface plasmon resonance. Immune recognition of the C14 scTCR protein as an antigen revealed that limited regions of the TCR may be more likely to induce responsiveness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773544     DOI: 10.1074/jbc.M300628200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

2.  Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity.

Authors:  Jianya Y Huan; Roberto Meza-Romero; Jeffery L Mooney; Yuan K Chou; David M Edwards; Cathleen Rich; Jason M Link; Arthur A Vandenbark; Dennis N Bourdette; Hans-Peter Bächinger; Gregory G Burrows
Journal:  J Chem Technol Biotechnol       Date:  2004-10-12       Impact factor: 3.174

3.  A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.

Authors:  Arthur A Vandenbark; Roberto Meza-Romero; Gil Benedek; Shayne Andrew; Jianya Huan; Yuan K Chou; Abigail C Buenafe; Rony Dahan; Yoram Reiter; Jeffery L Mooney; Halina Offner; Gregory G Burrows
Journal:  J Autoimmun       Date:  2012-09-29       Impact factor: 7.094

4.  Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis.

Authors:  Gregory G Burrows; Roberto Meza-Romero; Jianya Huan; Sushmita Sinha; Jeffrey L Mooney; Arthur A Vandenbark; Halina Offner
Journal:  Metab Brain Dis       Date:  2012-03-07       Impact factor: 3.584

5.  Vaccination with single chain antigen receptors for islet-derived peptides presented on I-A(g7) delays diabetes in NOD mice by inducing anergy in self-reactiveT-cells.

Authors:  Werner Gurr; Margaret Shaw; Raimund I Herzog; Yanxia Li; Robert Sherwin
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

Review 6.  A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury.

Authors:  Arthur A Vandenbark; Roberto Meza-Romero; Gil Benedek; Halina Offner
Journal:  J Neuroinflammation       Date:  2019-01-23       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.